Fruquintinib treatment in adults with metastatic colorectal cancer in Poland

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study conducted in Poland to assess outcomes of fruquintinib in adults with metastatic colorectal cancer after at least two prior treatments. The primary end point is progression-free survival, with overall survival as a key secondary measure and attention to patient quality of life. There are no active interventional procedures beyond the standard drug program; data will be collected from medical records and patient consent. Enrollment is limited to patients who qualify under the national drug program and who provide informed consent. The study aims to characterize real-world effectiveness and safety in a routine clinical setting across multiple Polish centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult participants (aged 18 years and older) with mCRC who are eligible for treatment with fruquintinib under the national drug program B.4 and will receive fruquintinib as third or subsequent line treatment after progression on or intolerance to trifluride/tipiracil.
2. Participants who signed informed consent to participate in the study at the time of enrollment and prior to the fruquintinib treatment initiation.
3. Participants for whom adequate medical records are available to support the data collection requirements.

Exclusion Criteria:

1\. Participant currently participates or plans to participate in an interventional clinical trial.

Where it's running

• Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie, Klinika Chorob Metabolicznych i Immunoonkologii, Oddzial Onkologii Klinicznej
  Lublin, Lublin Voivodeship, Poland Recruiting
• Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu, Oddzial Onkologiczny z Pod. Dziennej Chemioterapii
  Przemyśl, Podkarpackie Voivodeship, Poland Recruiting
• Bialostockie Centrum Onkologii im. M. Sklodowskiej-Curie w Bialymstoku, Oddzial Onkologii Klinicznej im. dr E. Pileckiej z pododdzialem Chemioterapii Dziennej
  Bialystok, Podlaskie Voivodeship, Poland Recruiting
• Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej Curie, Oddzial Onkologii Klinicznej i Immunoonkologii z Pododdzialem Dziennym i Izb Przyjec
  Poznan, Greater Poland Voivodeship, Poland Not yet recruiting
• Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy, Ambulatorium Chemoterapii
  Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland Not yet recruiting
• Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Onkologii
  Krakow, Lesser Poland Voivodeship, Poland Not yet recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating a new treatment for advanced colorectal cancer

  This study is testing a new combination treatment for advanced colorectal cancer to see if it can help patients who haven't had success with other therapies.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT06979908

• Fruquintinib plus tislelizumab versus trifluridine/tipiracil plus bevacizumab for MSS/pMMR metastatic colorectal cancer without active liver metastases

  This trial tests whether combining fruquintinib with tislelizumab works better than trifluridine/tipiracil plus bevacizumab for adults with MSS/pMMR metastatic colorectal cancer who do not have active liver metastases.

  Recruiting at 15 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Linz and 22 other locations · NCT06856837

• Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer

  This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07920224

• Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies

  This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.

  Recruiting Phase 2 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT07896096

• Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX

  This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07888309

• Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer

  This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07884188

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.